Literature DB >> 20169438

The pharmacological treatment of opioid addiction--a clinical perspective.

Philipp Lobmaier1, Michael Gossop, Helge Waal, Jorgen Bramness.   

Abstract

This article reviews the main pharmacotherapies that are currently being used to treat opioid addiction. Treatments include detoxification using tapered methadone, buprenorphine, adrenergic agonists such as clonidine and lofexidine, and forms of rapid detoxification. In opioid maintenance treatment (OMT), methadone is most widely used. OMT with buprenorphine, buprenorphine-naloxone combination, or other opioid agonists is also discussed. The use of the opioid antagonists naloxone (for the treatment of intoxication and overdose) and oral and sustained-release formulations of naltrexone (for relapse prevention) is also considered. Although recent advances in the neurobiology of addictions may lead to the development of new pharmacotherapies for the treatment of addictive disorders, a major challenge lies in delivering existing treatments more effectively. Pharmacotherapy of opioid addiction alone is usually insufficient, and a complete treatment should also include effective psychosocial support or other interventions. Combining pharmacotherapies with psychosocial support strategies that are tailored to meet the patients' needs represents the best way to treat opioid addiction effectively.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20169438     DOI: 10.1007/s00228-010-0793-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  106 in total

1.  A controlled trial of buprenorphine treatment for opioid dependence.

Authors:  R E Johnson; J H Jaffe; P J Fudala
Journal:  JAMA       Date:  1992-05-27       Impact factor: 56.272

2.  Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy.

Authors:  Harald Eder; Reinhold Jagsch; Dominik Kraigher; Andjela Primorac; Nina Ebner; Gabriele Fischer
Journal:  Addiction       Date:  2005-08       Impact factor: 6.526

3.  Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.

Authors:  Hendree E Jones; Rolley E Johnson; Donald R Jasinski; Kevin E O'Grady; Christian A Chisholm; Robin E Choo; Michael Crocetti; Robert Dudas; Cheryl Harrow; Marilyn A Huestis; Lauren M Jansson; Michael Lantz; Barry M Lester; Lorraine Milio
Journal:  Drug Alcohol Depend       Date:  2005-07       Impact factor: 4.492

4.  Buprenorphine prescription by general practitioners in a French region.

Authors:  X Thirion; V Lapierre; J Micallef; E Ronflé; A Masut; V Pradel; C Coudert; J C Mabriez; J L Sanmarco
Journal:  Drug Alcohol Depend       Date:  2002-01-01       Impact factor: 4.492

Review 5.  Methadone at tapered doses for the management of opioid withdrawal.

Authors:  L Amato; M Davoli; S Minozzi; R Ali; M Ferri
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

6.  Acute administration of buprenorphine in humans: partial agonist and blockade effects.

Authors:  S L Walsh; K L Preston; G E Bigelow; M L Stitzer
Journal:  J Pharmacol Exp Ther       Date:  1995-07       Impact factor: 4.030

7.  Buprenorphine antagonism of ventilatory depression following fentanyl anaesthesia.

Authors:  K Boysen; S Hertel; B Chraemmer-Jørgensen; A Risbo; N J Poulsen
Journal:  Acta Anaesthesiol Scand       Date:  1988-08       Impact factor: 2.105

Review 8.  Sustained-release naltrexone for opioid dependence.

Authors:  P Lobmaier; H Kornør; N Kunøe; A Bjørndal
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

9.  Codeine and clinical impairment in samples in which morphine is not detected.

Authors:  Liliana Bachs; Svetlana Skurtveit; Jørg Mørland
Journal:  Eur J Clin Pharmacol       Date:  2003-03-01       Impact factor: 2.953

Review 10.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08
View more
  45 in total

1.  Chronic methadone treatment shows a better cost/benefit ratio than chronic morphine in mice.

Authors:  Johan Enquist; Madeline Ferwerda; Laura Milan-Lobo; Jennifer L Whistler
Journal:  J Pharmacol Exp Ther       Date:  2011-11-07       Impact factor: 4.030

2.  Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).

Authors:  Evan D Kharasch; Pamela Sheffels Bedynek; Christine Hoffer; Alysa Walker; Dale Whittington
Journal:  Anesthesiology       Date:  2012-02       Impact factor: 7.892

Review 3.  Addiction and brain reward and antireward pathways.

Authors:  Eliot L Gardner
Journal:  Adv Psychosom Med       Date:  2011-04-19

Review 4.  The treatment of alcohol and opioid dependence in pregnant women.

Authors:  Annemarie Heberlein; Lorenzo Leggio; Dirk Stichtenoth; Thomas Hillemacher
Journal:  Curr Opin Psychiatry       Date:  2012-11       Impact factor: 4.741

5.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

Authors:  Yan Zhang; Amanda Braithwaite; Yunyun Yuan; John M Streicher; Edward J Bilsky
Journal:  Eur J Pharmacol       Date:  2014-05-08       Impact factor: 4.432

6.  High-sensitivity analysis of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in plasma and urine by liquid chromatography-mass spectrometry.

Authors:  Karen J Regina; Evan D Kharasch
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-09-08       Impact factor: 3.205

7.  Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats.

Authors:  M D Raleigh; M Pravetoni; A C Harris; A K Birnbaum; P R Pentel
Journal:  J Pharmacol Exp Ther       Date:  2012-12-07       Impact factor: 4.030

Review 8.  Methadone at tapered doses for the management of opioid withdrawal.

Authors:  Laura Amato; Marina Davoli; Silvia Minozzi; Eliana Ferroni; Robert Ali; Marica Ferri
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

9.  Automated radiochemical synthesis and biodistribution of [¹¹C]l-α-acetylmethadol ([¹¹C]LAAM).

Authors:  Kiran Kumar Solingapuram Sai; Jinda Fan; Zhude Tu; Patrick Zerkel; Robert H Mach; Evan D Kharasch
Journal:  Appl Radiat Isot       Date:  2014-06-02       Impact factor: 1.513

Review 10.  Advancing addiction treatment: what can we learn from animal studies?

Authors:  Peter H Wu; Kalynn M Schulz
Journal:  ILAR J       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.